论文部分内容阅读
目的:探究氯雷他定联合布地奈德鼻喷剂治疗过敏性鼻炎的临床疗效及对Th1/Th2细胞因子的影响。方法:选取我院2016年1月至2017年1月收治的过敏性鼻炎患者110例,按随机数字法分为实验组与对照组,两组均为55例。对照组的治疗方法为采用氯雷他定,实验组治疗则在对照组的基础上联合布地奈德鼻喷剂,30 d为一个疗程。对比两组患者治疗30d后的临床疗效、症状缓解时间和不良反应情况,以及治疗前、治疗30 d后Th1/Th2细胞因子白介素-4(IL-4)、γ-干扰素(IFN-γ)的表达水平。结果:治疗30 d后的总有效率,实验组显著高于对照组(P<0.05),实验组喷嚏、流涕、鼻痒症状缓解时间显著短于对照组(P<0.05),两组疲劳感、肠胃不适、头痛、皮疹发生率比较无统计学差异(P>0.05);治疗30d后两组IL-4表达水平显著低于治疗前(P<0.05),IFN-γ表达水平显著高于治疗前(P<0.05),实验组IL-4表达水平显著低于对照组(P<0.05),IFN-γ表达水平显著高于对照组(P<0.05)。结论:氯雷他定联合布地奈德鼻喷剂治疗过敏性鼻炎疗效较好,可显著改善患者临床症状,增强患者免疫功能,安全性较好,值得临床推广。
Objective: To investigate the clinical efficacy of loratadine combined with budesonide nasal spray in the treatment of allergic rhinitis and its effect on Th1 / Th2 cytokines. Methods: One hundred and ten patients with allergic rhinitis admitted from January 2016 to January 2017 in our hospital were divided into experimental group and control group according to random number method, 55 cases in both groups. The control group was treated with loratadine, and the experimental group was treated with budesonide nasal spray on the basis of the control group, 30 days for a course of treatment. Thirty-two days after treatment, the levels of IL-4, IFN-γ, Th1 / Th2 cytokines were compared between the two groups after 30 days of treatment. The level of expression. Results: The total effective rate after 30 days of treatment was significantly higher in the experimental group than in the control group (P <0.05). The relieving time of sneezing, runny nose and nasal itching in the experimental group was significantly shorter than that of the control group (P <0.05) (P> 0.05). After the treatment for 30 days, the expression of IL-4 in the two groups was significantly lower than that before treatment (P <0.05), and the level of IFN-γ was significantly higher than that before treatment The levels of IL-4 in the experimental group were significantly lower than those in the control group (P <0.05), and the levels of IFN-γ in the experimental group were significantly higher than those in the control group before treatment (P <0.05). Conclusion: The combination of loratadine and budesonide nasal spray is effective in treating allergic rhinitis, which can significantly improve the clinical symptoms and enhance the immune function of patients. It is safe and worthy of clinical promotion.